VG Life Sciences Inc. announced that it has signed a two-year commitment to provide funding toward the operational needs of the company from current investor MedBridge, LLC. During this period, MedBridge will also provide full administrative support for VG Life Sciences, allowing the company to focus on clinical development of its therapeutic pipeline.

MedBridge President and CEO David Odell will join VG Life Sciences' Board of Directors, as will John Tynan, President of the TynanGroup Companies, who is also a long-time investor in the company.